Skip to main content
CLVT logo

CLVT · Clarivate PLC

Track CLVT — free
$1.88 -0.03 (-1.57%)
Market Cap
$1.20B
Shares
639.22M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.91 Open$1.91 Day$1.84–1.92 52W close$1.68–4.19 Avg vol 30d4.3M Short int49.5M · 7.7% float · 12.2d Short vol41% Last earningsJul 29, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 6 wks
filed Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.45B
Trailing 12 months
Net income (TTM)
−$137.40M
Trailing 12 months
Revenue growth YoY
-1.4%
Year over year
Operating margin
5.0%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
27.8%
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
-7.1%
Year over year · fewer shares
Price change (1Y)
-55.5%
Trailing year
Short interest
7.7%
Latest settlement · 12.2 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Clarivate reaffirmed its full-year 2026 outlook, expecting ~200 bps adjusted EBITDA margin expansion and ~$900M of debt paydown, while Q2 net loss widened to $268.6M due to a $221.7M non-cash goodwill impairment linked to the pending Life Sciences & Healthcare divestiture.

Bullish
  • + Full-year 2026 outlook reaffirmed with adjusted EBITDA margin guided to expand ~200 bps
  • + Free cash flow guided at low end of $365M–$435M range with plan to retire ~$900M of debt using FCF and LS&H divestiture proceeds
  • + H1 adjusted EBITDA margin expanded 90 bps to 41.6% on recurring growth and cost discipline
  • + Total debt reduced by $218.4M in H1 via opportunistic repurchases at a discount to par
  • + Organic ACV grew 1.5% with H1 subscription organic growth up 60 bps YoY to 1.2%
Bearish
  • Q2 GAAP net loss widened to $268.6M ($0.42/share) on a $221.7M non-cash goodwill impairment tied to the LS&H divestiture
  • Q2 Adjusted EBITDA declined 5.5% to $247.2M, with H1 free cash flow down 23.5% to $122.9M
  • Full-year 2026 free cash flow guided to be flat YoY at low end of range due to ~$70M of one-time LS&H transaction costs
  • H1 operating cash flow declined 18.8% to $233.4M driven by lower EBITDA and higher working capital use

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.67
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −24%
below
Price vs 50-day avg −8%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 9%
near low
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −25%
trailing
YTD return −43%
this year
Relative strength −41%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +54 funds added
Insider flow Distributing
Net -$3.2M over 90 days · 50% sells
Short interest Falling
7.75% of float · ▼ -3.0% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
242 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
EPS growth +69%
Y/Y
Free cash flow $365.3M
Buyback $350.5M
remaining
Balance sheet $5.1B
net debt
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −61%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 29, 2026
Full Year 2026
Recurring Organic Revenue Growth Non-GAAP Initiated 0.75% – 2.25%
Revenues, Including Discontinued Operations Non-GAAP Initiated $2.3B – $2.42B
Adjusted EBITDA Non-GAAP Initiated $980M – $1.04B
Adjusted EBITDA Margin Non-GAAP Initiated 42% – 43.5%
Free Cash Flow Non-GAAP Initiated $365M – $435M
Year Ending December 31, 2026 (Forecasted)
Adjusted diluted EPS Non-GAAP Initiated $0.70 – $0.80
Net income (loss) per share Initiated $-0.64 – $-0.54
prior FY $-0.30 midpoint −96.7% Y/Y
Prior guidance period ended · from the 8-K filed Aug 6, 2024
Revenues · 2024 Outlook $2.57B – $2.67B
Organic Revenue Growth · 2024 Outlook 0% – 2%
Adjusted EBITDA · 2024 Outlook $1.06B – $1.12B
Adjusted EBITDA Margin · 2024 Outlook 41% – 42%
Free Cash Flow · 2024 Outlook $420M – $500M
Profit Margin · FY 2024 41% – 42%
Adj. Diluted EPS · Year Ending December 31, 2024 $0.70 – $0.80
Guided vs delivered · last 1 settled
Revenues 2024 Outlook
guided $2.57B – $2.67B
$2.56B Miss −2.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−24% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +54 funds added
Insider flow Distributing
Net -$3.2M over 90 days · 50% sells
Short interest Falling
7.75% of float · ▼ -3.0% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
242 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 9% Range high $4
vs 200-day avg -24% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Information Technology Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLVT
Clarivate PLC
this stock
$1.20B -42.8% +0.6% 7.7%
IBM
International Business Machines Corp
$234.68B -15.9% +7.6% 22.1 2.3%
ACN
Accenture plc
$122.81B -27.3% +7.4% 14.7 3.8%
INFY
Infosys Ltd
$46.98B -34.9% 3.2%
CTSH
Cognizant Technology Solutions Corp
$30.24B -22.8% +7.0% 13.8 7.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
242
% held
91.2%
Net QoQ
+15.7M sh
Top holder
Leonard Green & Partners,…
Held Float
View
Held by Funds
Fund positions
67
View
Short & Settlement
Short Interest Falling
Shares short
49.5M
Days to cover
12.2d
Change
-1.5M sh
View
Short Volume
Short vol %
41%
As of
Sep 14, 2026
Short Total
View
Fails to Deliver
FTD shares
1.7K
Value
$3.5K
As of
Aug 27, 2026
View
Off-Exchange
Off-exchange %
46.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.2M
Buyers / Sellers
1 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 12, 2023
View
Financials
Financials
Revenue (FY)
$2.5B
Net income (FY)
$-201.1M
EPS diluted
$-0.30
View
Buybacks
Authorized
$500.0M
Remaining
$350.5M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 29, 2026
This year
15
View
Proposed Sales
Value
$1.2M
Shares
309.9K
Filed
Dec 1, 2025
View
Earnings & Events
Earnings Calls
Last call
Jul 29, 2026
View
Investor Relations
Latest news
Clarivate Scales Agentic AI Acros…
Published
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
CLVT -7.7% -1.0% -25.1% -6.8% -42.8%
SPY -1.2% -2.0% +16.1% -0.8% +11.6%
vs SPY -6.5% +1.0% -41.2% -6.0% -54.4%

Capital returns

Buyback program · as of Sep 30, 2025
Authorized
$500.00M
Spent (derived)
$149.50M
Remaining
$350.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1764046 CUSIP G21810109 13F (30d) 15 filings 14 filers Visit website Investor relations